plaque psoriasis psoriasis
Conditions
Interventions
n.v.t.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients: In order to be eligible to participate in this study, a patient must meet all of the following criteria: - Women aged 18-45 year - Diagnosis of psoriasis - Using adalimumab, certolizumab, ustekinumab, ixekizumab, guselkumab or methotrexate for at least 6 months, or topical treatment. Healthy controls: In order to be eligible to participate in this study, a healthy control must meet the following criteria: - Women aged 18-45 year.
Exclusion criteria
Exclusion criteria: Patients: A potential patient who meets any of the following criteria will be excluded from participation in this study: - Use of other birth control than oral contraceptives (i.e., (copper) intra-uterine devices (IUD)) - Immune mediated co-morbidities (e.g., inflammatory bowel disease, rheumatoid arthritis) or diabetes mellitus - Smoking - Participants who are not capable of signing the informed consent Only for patients treated with biologics the following is also applicable: - Primary indication of biologic is not psoriasis. - Use of other immunomodulating medication, such as methotrexate, or antidepressants. Only for patients treated with methotrexate the following is also applicable: - Primary indication of methotrexate is not psoriasis. - Use of other immunomodulating medication, such as biologics, or antidepressants. Only for patients with topical treatment the following is also applicable: - Use of any systemic medication that is prescribed for psoriasis, such as biologics or methotrexate, or antidepressants. Healthy controls: A potential healthy control who meets any of the following criteria will be excluded from participation in this study: - Use of other birth control than oral contraceptives (i.e., copper intra-uterine device (IUD)) - Use of immunomodulating medication or antidepressants - Diagnosed with an autoimmune disease or diabetes mellitus - Known disorder of reproduction - Smoking - Participants who are not capable of signing the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in phenotype and function of immune cells present in the menstrual blood between patients with psoriasis using biologics, patients with psoriasis using methotrexate, patients with psoriasis using only topical medication and healthy controls. | — |
Countries
Netherlands
Contacts
Public ContactJMPA van den Reek
Radboud Universitair Medisch Centrum
Outcome results
None listed